Latest Ebola News

Page 1 of 3
Island Pharmaceuticals is moving Galidesivir into a decisive sequence of Marburg animal studies after the FDA confirmed an Animal Rule pathway for the antiviral. The company also expects to generate prospective human data through an approved Uganda Ebola program, although approval, funding and commercial outcomes remain unresolved.
Victor Sage
Victor Sage
17 Nov 2026
Ansell has entered FY27 with stronger margins, cash generation and shareholder distributions after adjusted EBIT rose 14.9% organically in FY26. The PPE maker is maintaining adjusted EPS guidance of 158 to 170 US cents while targeting further growth from US markets, productivity and a simpler product range.
Victor Sage
Victor Sage
9 Nov 2026
Island Pharmaceuticals has secured approvals to use Galidesivir in Uganda’s Bundibugyo Ebola outbreak while advancing two complementary Marburg studies and expanding manufacturing. The progress comes with a sharper funding question: cash fell to A$7.83 million after quarterly operating outflows of A$4.93 million, leaving an estimated 1.6 quarters of funding.
Victor Sage
Victor Sage
26 Oct 2026
Island Pharmaceuticals has begun GMP production of Galidesivir, with the first 5kg batch targeted for an investigational Ebola treatment program in Uganda. A second batch is intended to support a pivotal Marburg animal study under the FDA’s Animal Rule pathway.
Victor Sage
Victor Sage
2 Oct 2026
Island Pharmaceuticals has obtained regulatory rights to reference critical Marburg-Angola virus natural history data, clearing a significant FDA hurdle for its antiviral Galidesivir. This milestone accelerates the path toward pivotal animal studies and potential FDA approval under the Animal Rule.
Victor Sage
Victor Sage
31 Aug 2026
Island Pharmaceuticals has commissioned a second manufacturing run of its antiviral Galidesivir, aiming to stockpile up to 800 treatment courses by late 2026 to support rapid response to the fast-spreading Bundibugyo Ebola outbreak and biodefence efforts.
Victor Sage
Victor Sage
21 Aug 2026
Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.
Victor Sage
Victor Sage
30 July 2026
Island Pharmaceuticals is progressing its broad-spectrum antiviral Galidesivir amid a severe Ebola outbreak, securing government approvals in Uganda and outlining a dual clinical and regulatory development pathway targeting multiple deadly filoviruses.
Ada Torres
Ada Torres
8 July 2026
Island Pharmaceuticals has won a key regulatory boost as the US FDA granted Orphan Drug Designation to Galidesivir for post-exposure prophylaxis of Marburg virus disease, enhancing its commercial and development prospects.
Victor Sage
Victor Sage
17 June 2026
Island Pharmaceuticals has presented encouraging Phase 2a results for its dengue antiviral ISLA-101, demonstrating safety, effective blood concentrations, and meaningful viral load reductions at the Asia Dengue Summit.
Ada Torres
Ada Torres
16 June 2026
Island Pharmaceuticals is accelerating development of its broad-spectrum antiviral Galidesivir, progressing clinical, regulatory, and manufacturing milestones under the FDA Animal Rule pathway with expanded USAMRIID collaboration and biodefence positioning.
Victor Sage
Victor Sage
11 June 2026
Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.
Victor Sage
Victor Sage
10 June 2026

Browse the archive

Full archive